Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Novartis AG — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.31 (market cap $162.00B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays a 3.31% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Novartis AG for 82 Days on average.
| IEMG | NVS | |
|---|---|---|
Market Cap | $162.00B | $268.57B |
Volume | 13,446,151 | 1,532,573 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $168.62 |
52-Week Low | $64.22 | $121.80 |
Typical Hold Time | 57 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.29, down 0.91% with bearish technical signals dominating. The ETF faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers and its appeal for long-term portfolio strategies despite higher volatility compared to developed market alternatives.
The outlook remains cautious given technical weakness, though emerging market exposure offers growth potential. Key risks include sector concentration in technology and emerging market volatility. Analyst comparisons favor IEMG for cost efficiency and performance, but investors should weigh higher drawdowns against return potential.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
